Abivax SA is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases, with a primary focus on inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease. The company’s lead drug candidate, obefazimod, is an orally administered, once-daily small molecule that enhances the expression of microRNA-124 (miR-124) to stabilize the immune response and regulate multiple inflammatory pathways. Obefazimod is currently in Phase 3 clinical development for moderately to severely active ulcerative colitis and in Phase 2b development for Crohn’s disease. The company maintains a proprietary library of miR-124 enhancers to generate follow-on compounds and is evaluating potential combination therapies with other agents. Abivax holds worldwide rights to obefazimod and retains development and commercialization rights, while exploring strategic partnerships for specific geographies. The company was founded in 2013 and has one wholly owned subsidiary, Abivax LLC, formed in 2023.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage abivax.com
Sector Healthcare IR page abivax.com/investors
Tags
inflammatory bowel disease, ulcerative colitis, crohn's disease, microrna-124, small molecule therapeutics, immune regulation, clinical-stage development, oral administration, obefazimod, Abivax LLC, miR-124, ENHANCE-CD
Press page —

Metrics

Valuation  
Market cap € 7.903B
Market cap (USD) $ 8.669B
P/E -16.36
PEG —
P/BV 19.00
P/S —
P/OCF -43.20
P/FCF -43.16
Dividend yield —
Turnover / mcap —
Returns  
ROE -135.6%
ROI -73.8%
ROIC -40.5%
Profit margin -7,354.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 29
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 4.57M 12.449M 4.621M 0 0
Net profit -336.102M -176.242M -147.74M -60.74M -42.452M
Free cash flow -161.271M -154.712M -97.395M -54.259M -45.095M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 114.7 6.66 9.83 — —
Price performance 12m 17.42 -0.32 — — —

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (EUR) 47.8M 48.3M 103M 147M 178M
Reported Apr 5, 2024 Apr 5, 2024 Apr 5, 2024 Mar 24, 2025 Mar 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax’s Chemistry, Manufacturing and Controls (“CMC”), Quality and Information Technology (“IT”) functions

•Cash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026, combined with €767.1 million in net proceeds from the early July underwritten public offering, provides cash runway into Q4 2029

•Royalty certificates buy-back completed in Q2 2026 materially reduces royalty overhang, further strengthening Abivax’s debt-free financial position and flexibility to support future commercialization efforts

Strengthening Leadership Team Ahead of Potential Commercialization

Fabio Cataldi, M.D., Chief Medical Officer, will be leaving Abivax in the fourth quarter of 2026. Chris Rabbat, Ph.D., who has led Global Medical Affairs since 2023, will succeed Dr. Cataldi as Chief Medical Officer, leading the medical organization as Abivax advances toward potential commercialization. Dr.

23.1 Consent of Orrick Herrington & Sutcliffe (Europe) LLP (included in Exhibit 5.1)

Statements in this Report on Form 6-K that are not strictly historical in nature, including statements regarding the Company’s expectations with respect to the closing of the Offering and the receipt of gross proceeds, are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including market risks and uncertainties and risks relating to the satisfaction of customary closing conditions for an offering of securities. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of this report. The Company undertakes no obligation to publicly update or revise the information in this report, including any forward-looking statements, except as may be required by law.

Abivax Reports Positive ABTECT Maintenance Bull 5 Bear 0 Clinical/regulatory

Part 2 Results for Obefazimod, Demonstrating

Meaningful Clinical Benefit in Refractory Ulcerative

Colitis Patients and Strengthening the Phase 3

Maintenance Safety Database

• Obefazimod delivered meaningful clinical benefit in a highly refractory ulcerative colitis (“UC”) population, with 37.2% of induction non-responders achieving clinical remission and 34.5% achieving endoscopic remission at Week 44 following continued 50 mg treatment

• Dose escalation to obefazimod 50 mg recaptured clinical remission in 45.5% of patients who relapsed during ABTECT Maintenance Part 1, supporting a practical dose-escalation strategy for regaining and sustaining disease control over time

• Across the integrated Phase 2 and Phase 3 UC program (1,704 patient-years of exposure), exposure-adjusted incidence rates (“EAIRs”) for malignancies excluding non-melanoma skin cancer (“NMSC”) were 0.35 and 0.64 events per 100 patient-years (“PYs”), and for NMSC were 0.59 and 0.64 events per 100 PYs in the all-active combined (50 mg + 25 mg) and 50 mg cohorts, respectively, all consistent with expected UC background rates

• In ABTECT Maintenance Part 2, EAIRs for malignancies excluding NMSC were 0.48 and 0

Prompts

Abivax SA (ticker ABVX), listed in United States.

ETFs Holding Abivax SA

ETF Weight in ETF Shares Market value As of
MEDI 1.60% 7,743 $ 698.419K Nov 12, 2026
ATFV 0.86% 12,840 $ 1.711M Jun 30, 2026
ORR 0.52% 22,999 $ 1.89M Nov 18, 2026
MSSM 0.26% 16,586 $ 1.853M Aug 31, 2026
BDVL short -0.16% -34,262 $ -2.9M Nov 16, 2026
TMED 0.12% 209 $ 27.851K Jun 30, 2026
APIE 0.02% 2,584 $ 288.71K Aug 31, 2026
ENHI 0.01% 18 $ 1,523.45 Nov 16, 2026
PINK 0.01% 220 $ 18.062K Nov 17, 2026
NPFE 0.00% 12 $ 1,499.04 Jul 31, 2026